44 related articles for article (PubMed ID: 18796377)
1. Partial response of Zercepac® plus capecitabine for postoperative multiple metastases of HER2-positive breast cancer.
Yu J
Minerva Med; 2023 Dec; 114(6):887-888. PubMed ID: 35785950
[No Abstract] [Full Text] [Related]
2. Cutaneous metastases from breast carcinoma.
Ahmed M
BMJ Case Rep; 2011 Jul; 2011():. PubMed ID: 22689852
[TBL] [Abstract][Full Text] [Related]
3. Early Trastuzumab Interruption and Recurrence-Free Survival in ERBB2-Positive Breast Cancer.
Copeland-Halperin RS; Al-Sadawi M; Patil S; Liu JE; Steingart RM; Dang CT; Yu AF
JAMA Oncol; 2020 Dec; 6(12):1971-1972. PubMed ID: 33057570
[TBL] [Abstract][Full Text] [Related]
4. [A Case of COVID-19 Infection during Postoperative Chemotherapy for Breast Cancer Treated with Antibody Cocktail Therapy to Prevent Disease Aggravation].
Takashima Y; Terasawa R; Hirata A; Morita S; Kimura K; Iwamoto M; Hayashi M
Gan To Kagaku Ryoho; 2023 Sep; 50(9):1009-1011. PubMed ID: 37800299
[TBL] [Abstract][Full Text] [Related]
5. Impact of low estrogen/progesterone receptor expression on survival outcomes in breast cancers previously classified as triple negative breast cancers.
Raghav KP; Hernandez-Aya LF; Lei X; Chavez-Macgregor M; Meric-Bernstam F; Buchholz TA; Sahin A; Do KA; Hortobagyi GN; Gonzalez-Angulo AM
Cancer; 2012 Mar; 118(6):1498-506. PubMed ID: 21837669
[TBL] [Abstract][Full Text] [Related]
6. Genome-wide profiling of HPV integration in cervical cancer identifies clustered genomic hot spots and a potential microhomology-mediated integration mechanism.
Hu Z; Zhu D; Wang W; Li W; Jia W; Zeng X; Ding W; Yu L; Wang X; Wang L; Shen H; Zhang C; Liu H; Liu X; Zhao Y; Fang X; Li S; Chen W; Tang T; Fu A; Wang Z; Chen G; Gao Q; Li S; Xi L; Wang C; Liao S; Ma X; Wu P; Li K; Wang S; Zhou J; Wang J; Xu X; Wang H; Ma D
Nat Genet; 2015 Feb; 47(2):158-63. PubMed ID: 25581428
[TBL] [Abstract][Full Text] [Related]
7. Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression.
Balduzzi A; Bagnardi V; Rotmensz N; Dellapasqua S; Montagna E; Cardillo A; Viale G; Veronesi P; Intra M; Luini A; Pruneri G; Mastropasqua G; Goldhirsch A; Colleoni M
Clin Breast Cancer; 2014 Aug; 14(4):258-64. PubMed ID: 24325948
[TBL] [Abstract][Full Text] [Related]
8. Proto-oncogene c-erbB2 initiates rat primordial follicle growth via PKC and MAPK pathways.
Li-Ping Z; Da-Lei Z; Jian H; Liang-Quan X; Ai-Xia X; Xiao-Yu D; Dan-Feng T; Yue-Hui Z
Reprod Biol Endocrinol; 2010 Jun; 8():66. PubMed ID: 20565902
[TBL] [Abstract][Full Text] [Related]
9. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
[TBL] [Abstract][Full Text] [Related]
10. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Cameron DA; Stein S
Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
[TBL] [Abstract][Full Text] [Related]
11. Bilateral inflammatory metachronic ERBB2 (HER2/neu)-positive breast carcinoma: prolonged survival with combined chemotherapy and trastuzumab.
Lázaro A; Casinello J; Amorós A; Heredia M; López-Alfonso A
Clin Transl Oncol; 2008 Sep; 10(9):587-90. PubMed ID: 18796377
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes.
Ishida T; Kiba T; Takeda M; Matsuyama K; Teramukai S; Ishiwata R; Masuda N; Takatsuka Y; Noguchi S; Ishioka C; Fukushima M; Ohuchi N
Cancer Chemother Pharmacol; 2009 Jul; 64(2):361-9. PubMed ID: 19082596
[TBL] [Abstract][Full Text] [Related]
13. Complete remission of recurrent breast cancer with multiple liver metastases after oral capecitabine and injected trastuzumab.
Morohashi S; Odagiri H; Morohashi H; Kimura Y; Sasaki M
Breast Cancer; 2007; 14(3):297-301. PubMed ID: 17690508
[TBL] [Abstract][Full Text] [Related]
14. Metastatic breast cancer treated with lapatinib with a prolonged benefit: a case report and a review of therapeutic options available.
Bianchi GV; Duca M; Sica L; Mariani G
Tumori; 2013; 99(6):269e-72e. PubMed ID: 24503801
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
